9amHealth launches initiative to encourage more Americans to take the American Diabetes Association's Risk Test – Yahoo Finance

9amHealth, a fast-growing, all-in-one solution for people living with diabetes, prediabetes, and co-conditions, is proud to support the American Diabetes Association’s mission to prevent and cure diabetes.
SAN DIEGO, Jan. 9, 2023 /PRNewswire/ — 9amHealth has committed to a new initiative that provides clear steps and solutions for improving the long-term health of people living with diabetes. As part of the initiative, 9amHealth will offer discounted A1c tests to people who take the 60-Second Type 2 Diabetes Risk Test from the American Diabetes Association^® (ADA), helping to form an actionable path towards diagnosis for the 81% of Americans with prediabetes who are unaware of their condition.
An accurate diagnosis is not the only barrier to care for most Americans. Medical costs are approximately 2.3 times higher for people living with diabetes. Affordability is one of 9amHealth’s greatest assets—the company’s unique, all-in-one solution streamlines the care process and cuts down on unnecessary costs for patients.
“One of our greatest concerns is the high percentage of undiagnosed people living with diabetes and we’re proud to support the ADA in their mission to spread awareness,” said Avantika Waring, Chief Medical Officer of 9amHealth. “By combining our resources, we’ll be able to help people at risk for diabetes take clear action to manage their health and ultimately influence the trajectory of one of the most prevalent chronic conditions in the United States.”
The ADA’s Type 2 Diabetes Risk Test informs people of their risk for diabetes and prediabetes—and in 2022, over 1.2 million people have taken it. 9amHealth will provide an important option for a next step following the online assessment, starting with affordable A1c tests. A1c tests help evaluate blood sugar levels over the past three months. It is a quick, convenient way to determine if a person has prediabetes or diabetes.
“Undiagnosed diabetes is a major healthcare concern, especially for communities of color,” said Chuck Henderson, CEO of the ADA. “Our online risk assessment and the 9amHealth care model play an essential role in removing barriers to care. We are proud to connect with 9amHealth and better reach underserved communities.”
Based on the individual’s A1c results, 9amHealth will present a variety of medical care options—ranging from lab tests to all-in-one care plans. The 9am Care Team consists of top medical experts, pharmacists, and care professionals who have first-hand experience living with diabetes and navigating the healthcare system. Patients receive unlimited access to their Care Team, delivered prescription medications and devices, weight management guidance, and at-home labs. All done from the convenience of their homes. Those interested in taking the ADA’s 60-Second Type 2 Diabetes Risk Test for themselves or for a loved one can visit diabetes.org/diabetes/risk-test.
 
About 9amHealth
9amHealth offers a seamless, virtual solution to people living with type 2 diabetes, prediabetes, high blood pressure, and high cholesterol. The personalized membership plans include same-day prescriptions with at-home delivery and at-home labs, unlimited virtual access to medical experts, lifestyle guidance, and more. 9amHealth was founded in 2021 by the team behind mySugr, and is backed by 7Wire Ventures, Human Capital, Founders Fund, and Define Ventures. Since its launch in September 2021, 9amHealth has expanded its services from a direct-to-consumer offering to employers, health plans, and health systems. To learn more, please visit www.join9am.com.
About the American Diabetes Association
The American Diabetes Association (ADA) is the nation’s leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 82 years, the ADA has driven discovery and research to treat, manage, and prevent diabetes while working relentlessly for a cure. Through advocacy, program development, and education we aim to improve the quality of life for the over 133 million Americans living with diabetes or prediabetes. Diabetes has brought us together, what we do next will make us Connected for Life®. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), Twitter (@AmDiabetesAssn), and Instagram (@AmDiabetesAssn).
View original content:https://www.prnewswire.com/news-releases/9amhealth-launches-initiative-to-encourage-more-americans-to-take-the-american-diabetes-associations-risk-test-301715906.html
SOURCE 9amHealth
FDA approves Biogen (BIIB) and Eisai's lecanemab on an accelerated basis. Eisai filed a supplemental biologics license application (sBLA) to the FDA to get a traditional approval for Leqembi.
The Cambridge gene-editing company is laying off 20% of its workforce as it cuts drug programs geared toward retinal diseases and solid tumors.
With rates rising, biotech has faded. Investors have favored the pharma stalwarts. Bank of America’s drug analyst Geoff Meacham runs through the one’s to watch and a few to avoid. Plus: Could it be another banner year for Devon Energy?
Last year, the Nasdaq Composite experienced a downturn due to a combination of negative economic and political factors. At any rate, economic issues won't last forever, and the market will eventually continue its march forward. One growth stock that can help with that is none other than DexCom (NASDAQ: DXCM).
Ipsen is set to acquire Albireo Pharma Inc., the rare liver disease-focused biopharma spun out of AstraZeneca in 2008, for about $952 million.
Neurocrine Biosciences Inc (NASDAQ: NBIX) and Voyager Therapeutics Inc (NASDAQ: VYGR) have formed a new strategic collaboration to advance multiple gene therapies for neurological diseases. Voyager will receive up-front consideration of $175 million, including a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potential commercial milestones, tiered royalties on net sales, program funding, and an option to elect 50/50 cost- and profit-sharing in t
Belite Bio (NASDAQ: BLTE), TransMedics Group (NASDAQ: TMDX) and Rhythm Pharmaceuticals (NASDAQ: RYTM) set themselves apart over the past year with triple-digit share price gains. Each of the healthcare companies is developing something unique, whether it be finding treatments for maladies with no approved treatments, a more effective way to do organ transplants, or a more precise way to treat disorders that lead to obesity. Belite Bio is a clinical-stage biopharmaceutical company that focuses on therapies to treat blindness, diabetes, and liver disease.
Day One Biopharmaceuticals (NASDAQ: DAWN) announced topline results from the ongoing Phase 2 FIREFLY-1 trial evaluating tovorafenib (DAY101) as a monotherapy in recurrent or progressive pediatric low-grade glioma (pLGG). Pediatric low-grade glioma is the most common brain tumor diagnosed in children. Additional data will be submitted for presentation at an upcoming medical meeting in the second quarter of 2023. Overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% were observ
Israel based real-world study shows that omicron-targeted COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) reduced hospitalizations among older patients. The study has not yet been peer-reviewed. Data exhibited an 81% reduction in hospitalizations among people aged 65 and older who had received the booster against those who had previously received at least two COVID vaccinations but not the omicron-adapted shot. Related: FDA Authorizes Pfizer/BioNTech And Moderna's Biv
The CEO of the Mass. chapter of the Alzheimer's Association calls the FDA's approval of Leqembi last week "a disease paradigm change."
MARKET PULSE Shares of Day One Pharmaceuticals Inc. (DAWN) jumped 21% in premarket trading on Monday after the company shared positive data from an ongoing Phase 2 clinical trial for its glioma treatment.
Liver disease caused by excessive alcohol use has surged among young people, especially those between the ages of 25 to 34.
After having pancreatic cancer twice, Charles Czajkowski is dedicating the rest of his life to raising awareness of the early symptoms
When Dr. Emi Hosoda sees patients struggling to lose weight, she knows what they’re going through.
In this article, we take a look at the 15 most advanced countries in medicine. You can skip our detailed analysis of the healthcare industry and go directly to 5 Most Advanced Countries in Medicine. The recent pandemic was the best reflection of the advancements in the field of medicine. Vaccines were developed at a […]
New research shows that walking just 8,600 steps per day can lead to weight loss and lower your chances of developing chronic diseases.
(Bloomberg) — In the past three years, biotech companies have enjoyed a raft of successes, including rapidly developing vaccines for Covid-19, discovering a drug that can slow the progress of Alzheimer’s disease and securing approvals for one-time gene therapies for hard-to-treat conditions.Most Read from BloombergUS Safety Agency to Consider Ban on Gas Stoves Amid Health FearsGoldman to Cut About 3,200 Jobs This Week After Cost ReviewCommodity Ship Heads for Inspection After Suez Canal MishapS
The lawsuit says the addictive nature of apps has increased anxiety, self-harm, and depression.
Tumor cells traverse many different types of fluids as they travel through the body. Christoph Burgstedt/Science Photo Library via Getty ImagesCell migration, or how cells move in the body, is essential to both normal body function and disease progression. Cell movement is what allows body parts to grow in the right place during early development, wounds to heal and tumors to become metastatic. Over the last century, how researchers understood cell migration was limited to the effects of biochem
Damar Hamlin is now back home in Buffalo.

source